<DOC>
	<DOC>NCT02466919</DOC>
	<brief_summary>The study aims to evaluate H. pylori eradication rate in diabetic patients by using novel 10-day levofloxacin-based concomitant therapy compared with conventional 10-day sequential therapy.</brief_summary>
	<brief_title>Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Diabetic patients with Helicobacter pylori infection Pregnancy or physically poor performance status Patients with contraindication for upper endoscopy Severe coagulopathy for endoscopic biopsy Chronic kidney disease (eGFR &lt; 50) or end stage renal disease Known allergy to interventional drugs Previous eradication failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Helicobacter pylori</keyword>
</DOC>